Comprehensive report of the efficacy, safety, quality of life, and work impact of Olopatadine 0.6% and Olopatadine 0.4% treatment in patients with seasonal allergic rhinitis

Allergy and Asthma Proceedings

Volumn 28, Issue 6, 2007, Pages 716-723

  Fairchild, Carol J ^a   Meltzer, Eli O ^b   Roland, Peter S ^c   Wells, David ^a   Drake, Margaret ^a   Wall, G Michael ^a  

^a ALCON RESEARCH LTD   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Activity impairment; Clinical trial; Nasal spray; Olopatadine; Quality of life; RQLQ; Seasonal allergic rhinitis; TNSS; Work impairment; WPAI

Indexed keywords

ANTIALLERGIC AGENT; DIBENZOXEPIN DERIVATIVE; OLOPATADINE;

ADULT; ARTICLE; DOUBLE BLIND PROCEDURE; FEMALE; HAY FEVER; HUMAN; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INTRANASAL; ADULT; ANTI-ALLERGIC AGENTS; DIBENZOXEPINS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHINITIS, ALLERGIC, SEASONAL;

EID: 38349110611     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2007.28.3062     Document Type: Article

References (24)

1. Agency for Healthcare Research and Quality. Management of allergic and nonallergic rhinitis. Evidence Report/Technology Assessment No. 54, US Department of Health and Human Services. 1-6. 2002.
2. Reed SD, Lee TA, and McCrory DC. The economic burden of allergic rhinitis - A critical evaluation of the literature. Pharmacoeonomics 22:345-361, 2004.
3. Storms W, Meltzer EO, Nathan RA, et al. The economic impact of allergic rhinitis. J Allergy Clin Immunol 99:S820-S824, 1997.
4. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 28:3-9, 2007.
5. Jumper EF, Guyatt GH, Griffith LE, et al. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 98:843-845, 1996.
6. Meltzer EO, Nathan RA, Seiner JC, et al. Quality of life and rhinitic symptoms: Results of a nationwide survey with the SF-36 and RQLQ questionnaires. J Allergy Clin Immunol 99: S815-S819, 1997.
7. Wilken JA, Berkowitz R, and Kane R. Decrements in vigilance and cognitive functioning associated with ragweed-induced allergic rhinitis. Ann Allergy Asthma Immunol 89:372-380, 2002.
8. Craig TJ, McCann JL, Gurevich F, et al. The correlation between allergic rhinitis and sleep disturbance. J Allergy Clin Immunol 114:8139-8145, 2004.
9. Ferguson BJ. Cost-effective pharmacotherapy for allergic rhinitis. Otolaryngol Clin North Am 31:91-110, 1998.
10. Reilly MC, Tanner A, and Meltzer EO. Work, classroom and activity impairment instruments - Validation studies in allergic rhinitis. Clin Drug Invest 11:278-288, 1996.
11. Howard KB, Bowers BW, Cook CK, et al. Intranasal fluticasone, loratadine tablets, and their use in combination: An evaluation of economic and humanistic outcomes. Drug Benefit Trends 13:45-52, 2001.
12. Jen A, Baroody F, deTineo M, et al. As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 105:732-738, 2000.
13. Ciprandi G, Canonica WG, Grosclaude M, et al. Effects of budesonide and fluticasone propionate in a placebo-controlled study on symptoms and quality of life in seasonal allergic rhinitis. Allergy 57:586-591, 2002.
14. Potter PC, Van Niekerk CH, and Schoeman HS. Effects of triamcinolone on quality of life in patients with persistent allergic rhinitis. Ann Allergy Asthma Immunol 91:368-374, 2003.
15. Gupchup GV, Borrego ME, Santos R, et al. Economic, patient preference, and health-related qualify of life considerations for intranasal corticosteroids in allergic rhinitis. Implications for managed care. Dis Manage Health Outcomes 13:169-184, 2005.
16. Ramer PH, Hampel FC, Amar NJ, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar. Ann Allergy Asthma Immunol 95:474-479, 2005.
17. Hampel FC Jr, Ratner PH, Amar NJ, et al. Improved quality of life among seasonal allergic rhinitis patients treated with olopatadine HC1 nasal spray 0.4% and olopatadine HC1 nasal spray 0.6% compared with vehicle placebo. Allergy Asthma Proc 27:202-207, 2006.
18. Meltzer EO, Hampel FC, Ratner PH, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 95: 600-606, 2005.
19. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 47:81-87, 1994.
20. Reilly MC, Zbrozek AS, and Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeonomics 4:353-365, 1993.
21. Juniper EF. Quality of life and rhinitis: Nothing to be sneezed at! Expert Rev Pharmacoecon Outcomes Res 1:121-123, 2001.
22. US Food and Drug Administration (FDA). US Food and Drug Administration Center for Drug Evaluation and Research. 20114S006 Astelin nasal spray medical review, section 9 Overview of Efficacy. 2000.
23. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Chap. 2. Hillsdale, NJ: Lawerence Erlbaum Assoc., 1988. p 40.
24. Astelin Prescribing Information. Available at www.astelin.com/Astelin. Public/AstelinPi.pdf; last accessed Nov. 3, 2007